ASCIA News
-
Updated 2020 versions of ASCIA Action Plans are now available
10 January 2020: ASCIA Action Plans for Anaphylaxis (RED) and ASCIA Action Plan for Allergic Reactions (GREEN) have been updated in January 2020 and are available at www.allergy.org.au/hp/anaphylaxis/ascia-action-plan-for-anaphylaxis The main update to ASCIA Action Plans was... -
ASCIA Highlights 2019
3 January 2020: As we enter a new decade in 2020, we take this opportunity to wish you a happy new year and reflect on the highlights of 2019. There were several highlights in 2019 for ASCIA, including: Highly acclaimed and successful meetings - ASCIA Annual Conference, ASCI... -
EpiPen® supply update
2 January 2020: Mylan, the supplier of 150 mcg EpiPen® Jr and 300 mcg EpiPen® adrenaline (epinephrine) autoinjectors in Australia and New Zealand, recently advised the Therapeutic Goods Administration (TGA) of the outcomes of testing of EpiPen® products. Meridian Medical Tec... -
NPS MedicineWise Immunoglobulin Consortium
16 December 2019: A new grant will fund a project which will increase national efforts to improve health outcomes for patients prescribed immunoglobulin products. This project involves the National Prescribing Service (NPS) MedicineWise and a consortium of health organisatio... -
Further important information about EpiPen® Jr Supply
5 December 2019: ASCIA has been notified that EpiPen® Jr will not be available from 5 December 2019. See notice from Mylan Australia here. People who are newly diagnosed or who have used their last EpiPen® Jr may not be able to purchase an EpiPen® Jr device until stock arriv... -
Important notice about EpiPen® Jr Supply
20 November 2019: Supply of EpiPen® Jr 150mcg adrenaline (epinephrine) autoinjectors has been affected due to manufacturing delays from the manufacturer in the US, Meridian Medical Technologies, a Pfizer company. This means that there is currently a shortage of EpiPen® Jr as... -
Parliamentary Inquiry into Allergies and Anaphylaxis
19 November 2019: There were two hearings this week for the Parliamentary Inquiry into Allergies and Anaphylaxis, in Melbourne on Monday 18th November 2019 (10am-5pm) and in Sydney on Tuesday 19th November 2019 (9.30-4.30pm). Hansard records of the hearings will soon be on t... -
ASCIA 2019 Conference Report
12 September 2019: The 30th ASCIA Annual Conference was a great success, with more than 600 registrations and an acclaimed program. Congratulations and thank you to Prof Michaela Lucas and the organising committee (Dr Chris Bundell, Rachael Dunn, A/Prof Mina John, A/Prof Ric...
About ASCIA
ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases
Quick Links
About ASCIA
ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...
The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...
Disclaimer I Privacy
The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...
ASCIA respects your privacy. Read our privacy policy here...
Sponsors | Advertising
ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.
The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.
Accreditiation
This site complies with the HONcode standard for trustworthy health information: verify here.